148 related articles for article (PubMed ID: 11170303)
1. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105.
Li C; Guo B; Bernabeu C; Kumar S
Microsc Res Tech; 2001 Feb; 52(4):437-49. PubMed ID: 11170303
[TBL] [Abstract][Full Text] [Related]
2. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis.
Li C; Gardy R; Seon BK; Duff SE; Abdalla S; Renehan A; O'Dwyer ST; Haboubi N; Kumar S
Br J Cancer; 2003 May; 88(9):1424-31. PubMed ID: 12778073
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
4. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
5. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells.
Li C; Hampson IN; Hampson L; Kumar P; Bernabeu C; Kumar S
FASEB J; 2000 Jan; 14(1):55-64. PubMed ID: 10627280
[TBL] [Abstract][Full Text] [Related]
6. Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer.
Li C; Wang J; Wilson PB; Kumar P; Levine E; Hunter RD; Kumar S
Int J Cancer; 1998 Oct; 79(5):455-9. PubMed ID: 9761112
[TBL] [Abstract][Full Text] [Related]
7. Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells.
Warrington K; Hillarby MC; Li C; Letarte M; Kumar S
Anticancer Res; 2005; 25(3B):1851-64. PubMed ID: 16158917
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
9. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
Li C; Guo B; Wilson PB; Stewart A; Byrne G; Bundred N; Kumar S
Int J Cancer; 2000 Mar; 89(2):122-6. PubMed ID: 10754488
[TBL] [Abstract][Full Text] [Related]
11. CD105 prevents apoptosis in hypoxic endothelial cells.
Li C; Issa R; Kumar P; Hampson IN; Lopez-Novoa JM; Bernabeu C; Kumar S
J Cell Sci; 2003 Jul; 116(Pt 13):2677-85. PubMed ID: 12746487
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
Fonsatti E; Sigalotti L; Arslan P; Altomonte M; Maio M
Curr Cancer Drug Targets; 2003 Dec; 3(6):427-32. PubMed ID: 14683500
[TBL] [Abstract][Full Text] [Related]
14. Immunodetection and characterisation of soluble CD105-TGFbeta complexes.
Li CG; Wilson PB; Bernabeu C; Raab U; Wang JM; Kumar S
J Immunol Methods; 1998 Sep; 218(1-2):85-93. PubMed ID: 9819125
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
17. Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Postiglione L; Di Domenico G; Caraglia M; Marra M; Giuberti G; Del Vecchio L; Montagnani S; Macri M; Bruno EM; Abbruzzese A; Rossi G
Int J Oncol; 2005 May; 26(5):1193-201. PubMed ID: 15809709
[TBL] [Abstract][Full Text] [Related]
18. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
[TBL] [Abstract][Full Text] [Related]
20. mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer.
Gómez-Esquer F; Agudo D; Martínez-Arribas F; Nuñez-Villar MJ; Schneider J
Anticancer Res; 2004; 24(3a):1581-5. PubMed ID: 15274325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
